OHR Pharmaceutical Inc.

Financials

v3.10.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2018
Sep. 30, 2017
CURRENT ASSETS    
Cash $ 4,435,427 $ 12,801,085
Prepaid expenses and other current assets 413,042 223,278
Total Current Assets 4,848,469 13,024,363
EQUIPMENT, net 18,106 63,757
OTHER ASSETS    
Security deposit   12,243
Intangible assets, net 13,205,264 14,087,602
Goodwill   740,912
TOTAL ASSETS 18,071,839 27,928,877
CURRENT LIABILITIES    
Accounts payable and accrued expenses 706,804 4,827,525
Notes payable 181,548 106,387
Total Current Liabilities 888,352 4,933,912
Long-term liabilities   150,000
TOTAL LIABILITIES 888,352 5,083,912
STOCKHOLDERS' EQUITY    
Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively  
Common stock; 180,000,000 shares authorized, $0.0001 par value, 56,466,428 and 56,196,428 shares issued and outstanding, respectively 5,647 5,619
Additional paid-in capital 132,147,600 130,927,953
Accumulated deficit (114,969,760) (108,088,607)
Total Stockholders' Equity 17,183,487 22,844,965
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 18,071,839 $ 27,928,877
v3.10.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
OPERATING EXPENSES        
General and administrative $ 834,703 $ 1,404,287 $ 2,935,919 $ 4,554,704
Research and development 52,630 2,233,388 4,242,307 13,158,460
Depreciation and amortization 279,008 288,976 842,519 879,286
Loss on Impairment of Goodwill     740,912  
Gain on settlement of liabilities   (70,757) (1,228,805) (70,757)
OPERATING LOSS 1,166,341 3,855,894 7,532,852 18,521,693
OTHER INCOME (EXPENSE)        
Other income (expense) 610,383 5,441 592,584 5,441
Interest income (expense), net 10,930 (50,376) 59,115 (50,303)
Total Other Income (Expense) 621,313 (44,935) 651,699 (44,862)
NET LOSS $ (545,028) $ (3,900,829) $ (6,881,153) $ (18,566,555)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (0.01) $ (0.07) $ (0.12) $ (0.45)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:        
BASIC AND DILUTED (in shares) 56,466,428 53,986,150 56,377,435 40,916,570
v3.10.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Jun. 30, 2018
Jun. 30, 2017
OPERATING ACTIVITIES    
Net loss $ (6,881,153) $ (18,566,555)
Adjustments to reconcile net loss to net cash used by operating activities:    
Common stock issued for services 145,301 783,842
Stock option expense 804,374 1,256,644
Depreciation 7,877 40,814
Amortization of intangible assets 834,642 838,472
Gain on settlement of liabilities 1,228,805 (70,757)
(Gain) loss on sale of property and equipment 17,814 (5,441)
(Gain) loss on sale of intangible assets (460,383)  
Loss on Impairment of Goodwill 740,912  
Changes in operating assets and liabilities    
Prepaid expenses and other current assets 165,533 444,036
Accounts payable and accrued expenses (5,499,525) 1,262,686
Net Cash Used in Operating Activities (8,895,803) (14,016,259)
INVESTING ACTIVITIES    
Purchase of property and equipment   (4,833)
Proceeds from sale of property and equipment and intangible assets 508,078 88,285
Net Cash Provided by/ (Used in) Investing Activities 508,078 83,452
FINANCING ACTIVITIES    
Proceeds for issuance of common stock for cash   19,537,001
Proceeds from warrants exercised for cash 270,000 118,801
Repayments of short-term notes payable (247,933) (190,479)
Net Cash Provided by/ (Used in) Financing Activities 22,067 19,465,323
NET CHANGE IN CASH (8,365,658) 5,532,516
CASH AT BEGINNING OF PERIOD 12,801,085 12,546,890
CASH AT END OF PERIOD 4,435,427 18,079,406
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION CASH PAID FOR:    
Interest 7,540 5,107
NON CASH FINANCING ACTIVITIES:    
Financing of insurance premiums through issuance of short term notes $ 323,094 $ 261,326